14. Cropley, V. L. et al. (2006). Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry, 59, 898-907.
15. Lewis, D. A. y Levitt, P. (2002). Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience, 25, 409-432.
16. Coyle, J. T. et al. (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Sciences, 1003, 318-327.
17. Flaum, M. et al. (1995). Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. American Journal of Psychiatry, 152, 704-714.
18. Garcia M. y Arango C. (2010). Neuroimagen y Neurofisiología de la Esquizofrenia. In J Vallejo y C.Leal (Eds.), Tratado de Psiquiatría (pp. 1029-1044). Barcelona: Ars Médica.
19. Goff, D. C. y Wine, L. (1997). Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research, 27, 157-168.
20. Javitt, D. C. y Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry , 148, 1301-1308.
21. Grace, A. A. (1991a). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 41, 1-24.
22. Grace, A. A. (1993). Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. Journal of Neural Transmission. General Section, 91, 111-134.
23. Laruelle, M. et al. (2003). Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals of the New York Academy of Sciences, 1003, 138-158.
24. Stephan, K. E. et al. (2006). Synaptic plasticity and dysconnection in schizophrenia. Biological Psychiatry, 59, 929-939.
25. Tsai, G. y Coyle, J. T. (2002). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology., 42, 165-179.
26. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S23-32.
27. S, Singh V Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia CNS Drugs 25(10):859-885, 2011
28. Rogawski MA, Wenk GL. The neuropharmacological basis for the useof memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9: 275-308
29. Erdö SL, Schafer M. Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991; 198: 215-7.
30. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993; 33: 403-7.
31. Heim C, Sontag KH. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl 1995; 46: 117-30.
32. Keilhoff G, Wolf G. Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol 1992; 219: 451-4.
33. Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247-58.
34. Elizagarate E, Sánchez P, Ojeda del Pozo, Ezcurra J, Mendiola N, Npal O, Peña J, Larumbe J, Investigación Comisionada. Victoria-Gasteiz. Departamento de sanidad y Consumo, Gobierno Vazco, 2012. Informe Nº Osteba D-12-04.
35. Rands DS. Memantine as a neuroprotective treatment in sxhiphrenia. Br J Psychiatry. 2005; 186-77; author reply 77-8.
36. Thomas C, Carroll BT, Maley RT, Jayanti K, Koduri A. Memantines and catatonic schtzophenia. Am J Psychiatry. 2005; 162(3);626.